论文部分内容阅读
目的 分析树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK细胞)免疫治疗联合紫杉醇腹腔灌注化疗对卵巢癌患者人附睾蛋白4(HE4)、碱性成纤维细胞生长因子(bFGF)、细胞角蛋白19血清片段21-1(CYFRA21-1)的影响.方法 选择2014年1—8月陕西省第二人民医院收治的晚期卵巢癌患者80例,按照抽签法分为常规化疗组(n=50)和免疫治疗组(n=30).常规化疗组采用紫杉醇常规腹腔灌注化疗;免疫治疗组采用DC-CIK细胞免疫治疗联合紫杉醇腹腔灌注化疗.比较两组患者HE4、bFGF和CYFRA21-1、糖类抗原(CA)19-9、CA125、甲胎蛋白(AFP)水平及不良反应发生情况.结果 治疗后,两组患者血清HE4、bFGF和CYFRA21-1、CA19-9、CA125、AFP水平均显著低于治疗前(P<0.01).治疗后,免疫治疗组患者血清HE4、bFGF和CYFRA21-1、CA19-9、CA125、AFP水平显著低于常规化疗组[(42.3±10.8)pmol/L比(87.9±25.6)pmol/L,(70.3±15.4)ng/L比(91.6±18.5)ng/L,(1.5±0.3)μg/L比(2.4±0.6)μg/L,(14.3±9.8)kU/L比(39.9±10.6)kU/L,(10.8±5.6)kU/L比(38.6±10.5)kU/L,(3.3±1.2)μg/L比(24.7±2.3)μg/L](P0.05).结论 DC-CIK细胞免疫治疗联合紫杉醇腹腔灌注化疗可显著降低卵巢癌患者HE4、bFGF和CYFRA21-1水平,且不增加不良反应.“,”Objective To analyze the influence of dendritic cells-cytokine induced killer cells immunotherapy in com-bination with paclitaxel intraperitoneal chemotherapy on human epididymis protein 4(HE4),basic fibroblast growth factor (bFGF) and cytokeratin fragments 21-1(CYFRA21-1) level of ovarian cancer patients .Methods A total of 80 patients with advanced ovarian cancer in the Second People′s Hospital of Shaanxi Province from Jan .to Aug.2014 were divided into a conventional chemotherapy group ( conventional intraperitoneal paclitaxel chemotherapy group , n=50 ) and an immuno-therapy group(DC-CIK cellular immunotherapy in combination with paclitaxel intraperitoneal chemotherapy group ,n=30) by sortition randomization method .HE4,bFGF and CYFRA21-1 levels and adverse events of the two groups were compared . Results After treatment,serum HE4,bFGF and CYFRA21-1 of the two groups were significantly lower than before treat-ment(P<0.01).After treatment,serum HE4,bFGF and CYFRA21-1,carbohydrate antigen (CA)19-9,CA125,alphafeto-protein( AFP) levels of the immunotherapy group were significantly lower than those in the conventional chemotherapy group [(42.3 ±10.8) pmol/L vs (87.9 ±25.6) pmol/L,(70.3 ±15.4) ng/L vs ( 91.6 ±18.5) ng/L,(1.5 ±0.3) μg/L vs (2.4 ±0.6) μg/L,(14.3 ±9.8) kU/L vs (39.9 ±10.6) kU/L,(10.8 ±5.6) kU/L vs (38.6 ±10.5) kU/L,(3.3 ± 1.2) μg/L vs (24.7 ±2.3)μg/L](P0.05).Conclusion DC-CIK cellular immunotherapy in combination with paclitaxel intraperitoneal chemotherapy can significantly reduce ovarian cancer patients ′HE4,bFGF and CYFRA21-1 levels without increasing adverse effects .